s 3 Section 2: supplementary
(1) In section 2, “ doctor ” means a registered medical practitioner. (2) For the purposes of section 2(2), the kinds of medical treatment that may be innovative medical treatments include (amongst other things)— (a) the off-label use of an authorised medicinal product, and (b) the use of a medicinal product in respect of which no UK marketing authorisation is in force. (3) In subsection (2)(a), the reference to the off-label use of an authorised medicinal product is a reference to the use of the product— (a) for a purpose other than one for which its use is specified, (b) in relation to a person who is not within a description of persons for whom its use is specified, or (c) in any other way in which its use is not specified. (4) In this section— (a) “ authorised medicinal product ” means a medicinal product in respect of which a UK marketing authorisation is in force; (b) “ UK marketing authorisation ” and “ medicinal product ” have the same meanings as in the Human Medicines Regulations 2012 ( S.I. 2012/1916); (c) “ specified ”, in relation to a medicinal product, means specified in its UK marketing authorisation. (5) References in section 2 to medical treatment include references to treatment carried out for the purposes of medical research (but nothing in section 2 is to be read as affecting the regulation of medical research). (6) Nothing in section 2 applies in relation to treatment which is carried out solely for cosmetic purposes.